Literature DB >> 2317947

Reduced natural cytotoxic cell activity in patients receiving cisplatin-based chemotherapy and in mice treated with cisplatin.

C B Powell1, D G Mutch, M S Kao, J L Collins.   

Abstract

In mice natural cytotoxic (NC) cells are known to play a role in the rejection of tumours that are sensitive to NC-mediated lysis. We have recently shown that in vitro human and murine tumour cells become more sensitive to lysis mediated by NC cells in the presence of the anti-cancer drug cisplatin. If NC activity plays a role in tumour surveillance in humans, then the ability of NC cells to eliminate tumours in patients treated with cisplatin would not only be dependent on cisplatin increasing the sensitivity of tumours to NC mediated lysis, but would also depend on the maintenance of high levels of NC activity during chemotherapy. Here we report that patients receiving chemotherapy that included cisplatin showed a time-dependent reduction in NC activity. NC activity was normal 1 day after treatment; however, 15 days after treatment patients had an eight- to 16-fold reduction in NC activity that returned to normal levels by day 21. The reduction in NC activity of patients was coincident with a reduction in circulating monocytes. Mice treated with only cisplatin showed a similar reduction in NC activity. Mice treated with cisplatin had a reduced level of NC activity that was first apparent 8 days after treatment, reached a nadir on day 15, and returned to normal levels on day 22.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317947      PMCID: PMC1534968          DOI: 10.1111/j.1365-2249.1990.tb08106.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  T-cell inhibition of humoral responsiveness. I. Experimental evidence for restriction by the K- and/or D-end of the H-2 gene complex.

Authors:  R Epstein; M Cohn
Journal:  Cell Immunol       Date:  1978-08       Impact factor: 4.868

2.  Evidence that cytotoxic T cells and natural cytotoxic cells use different lytic mechanisms to lyse the same targets.

Authors:  P Q Patek; J L Collins; M Cohn
Journal:  Eur J Immunol       Date:  1983-05       Impact factor: 5.532

3.  An analysis of the sensitivity of somatic cell hybrids to natural killer cell- and natural cytotoxic cell-mediated lysis.

Authors:  Y Lin; J L Collins; P Q Patek; M Cohn
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

4.  In vivo surveillance of tumorigenic cells transformed in vitro.

Authors:  J L Collins; P Q Patek; M Cohn
Journal:  Nature       Date:  1982-09-09       Impact factor: 49.962

5.  Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis.

Authors:  P Q Patek; J L Collins; M Cohn
Journal:  Nature       Date:  1978-11-30       Impact factor: 49.962

6.  Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man.

Authors:  W Scheithauer; G M Clark; S E Salmon; W Dorda; R H Shoemaker; D D Von Hoff
Journal:  Cancer Treat Rep       Date:  1986-12

7.  In vivo or in vitro selection for resistance to natural cytotoxic cell lysis selects for variants with increased tumorigenicity.

Authors:  P Q Patek; Y Lin; J L Collins; M Cohn
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

8.  Analysis of immune surveillance of sequentially derived cell lines that differ in their tumorigenic potential.

Authors:  Y Lin; P Q Patek; J L Collins; M Cohn
Journal:  J Natl Cancer Inst       Date:  1985-05       Impact factor: 13.506

9.  Normal levels of natural cytotoxic cells against solid tumours in NK-deficient beige mice.

Authors:  O Stutman; M J Cuttito
Journal:  Nature       Date:  1981-03-19       Impact factor: 49.962

10.  Tumorigenicity and lysis by natural killers.

Authors:  J L Collins; P Q Patek; M Cohn
Journal:  J Exp Med       Date:  1981-01-01       Impact factor: 14.307

View more
  3 in total

1.  Immunologic status in children with brain tumors and the effect of therapy.

Authors:  R Kebudi; I Ayan; E Darendeliler; L Ağaoğlu; S Ekmekçioğlu; T Yağci; S Pişkin; N Bilge
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

2.  Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer.

Authors:  H Onodera; S S Somers; P J Guillou
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

3.  PU.1 Mimic Synthetic Peptides Selectively Bind with GATA-1 and Allow c-Jun PU.1 Binding to Enhance Myelopoiesis.

Authors:  Pawan Kumar Raghav; Gurudutta Gangenahalli
Journal:  Int J Nanomedicine       Date:  2021-06-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.